TACHYCARDIA-INDUCED CARDIOMYOPATHY AS A POTENTIALLY REVERSIBLE CAUSE OF HEART FAILURE
Abstract
Cardiac arrhythmias often coexist with heart failure and can be its cause or a consequence. Tachycardia-induced cardiomyopathy most often occurs as a consequence of persistent atrial tachyarrhythmias, such as atrial fibrillation and atrial flutter. Accelerated heart rate leads to systolic and diastolic dysfunction of the left ventricle with its consequent dilation together with changes at the neurohumoral and cellular level. Clinical presentation varies from asymptomatic tachycardia to the end-stage heart failure. Tachycardia-induced cardiomyopathy is an often unrecognized and potentially reversible cause of heart failure. The exact prevalence of tachycardiomyopathy is difficult to determine because the diagnosis is made retrospectively, based on echocardiographically confirmed recovery of the left ventricular function after adequate treatment of the arrhythmia. The most effective treatment is catheter ablation of the arrhythmia. Other treatments include electrical cardioversion, pharmacological rhythm and/or rate control, and pacemaker implantation with ablation of the atrioventricular node.
References
1. Ellis ER, Josephson ME. What About Tachycardia-induced Cardiomyopathy? Arrhythm Electrophysiol Rev. 2013;2(2):82-90.
2. Phillips E, Levine SA. Auricular fibrillation without other evidence of heart disease; a cause of reversible heart failure. Am J Med. 1949;7(4):478-89.
3. Mohamed HA. Tachycardia-induced Cardiomyopathy (Tachycardiomyopathy). Libyan J Med. 2007;2(1):26-9.
4. Howard RJ, Stopps TP, Moe GW, Gotlieb A, Armstrong PW. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol. 1988;66(12):1505-12.
5. Morgan DE, Tomlinson CW, Qayumi AK, Toleikis PM, McConville B, Jamieson WR. Evaluation of ventricular contractility indexes in the dog with left ventricular dysfunction induced by rapid atrial pacing. J Am Coll Cardiol. 1989;14(2):489-95; discussion 96-8.
6. Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol. 1996;19(1):95-106.
7. Luchsinger JA, Steinberg JS. Resolution of cardiomyopathy after ablation of atrial flutter. J Am Coll Cardiol. 1998;32(1):205-10.
8. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498.
9. Kareti KR, Chiong JR, Hsu SS, Miller AB. Congestive heart failure and atrial fibrillation: rhythm versus rate control. J Card Fail. 2005;11(3):164-72.
10. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30(4):1039-45.
11. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003;91(6a):2d-8d.
12. Qin D, Mansour MC, Ruskin JN, Heist EK. Atrial Fibrillation-Mediated Cardiomyopathy. Circ Arrhythm Electrophysiol. 2019;12(12):e007809.
13. Mujović N, Grujić M, Mrdja S, Kocijančić A, Milašinović G, Jovanović V, et al. [Long-term follow-up after catheter-ablation of atrioventricular junction and pacemaker implantation in patients with uncontrolled atrial fibrillation and heart failure]. Srp Arh Celok Lek. 2011;139(9-10):591-8.
14. Gentlesk PJ, Sauer WH, Gerstenfeld EP, Lin D, Dixit S, Zado E, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(1):9-14.
15. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018;378(5):417-27.
16. Khan MN, Jaïs P, Cummings J, Di Biase L, Sanders P, Martin DO, et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359(17):1778-85.
17. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000;36(7):2242-6.
18. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol. 2009;104(11):1534-9.
19. Wellens HJ. Contemporary management of atrial flutter. Circulation. 2002;106(6):649-52.
20. Cosio FG. Atrial Flutter, Typical and Atypical: A Review. Arrhythm Electrophysiol Rev. 2017;6(2):55-62.
21. Yang Y, Cheng J, Bochoeyer A, Hamdan MH, Kowal RC, Page R, et al. Atypical right atrial flutter patterns. Circulation. 2001;103(25):3092-8.
22. Calkins H. Important Differences Exist Between Atrial Fibrillation and Atrial Flutter in Atrial Remodeling. J Am Coll Cardiol. 2020;76(4):389-90.
23. Hsieh MH, Tai CT, Chiang CE, Tsai CF, Yu WC, Chen YJ, et al. Recurrent atrial flutter and atrial fibrillation after catheter ablation of the cavotricuspid isthmus: a very long-term follow-up of 333 patients. J Interv Card Electrophysiol. 2002;7(3):225-31.
24. Diamant MJ, Andrade JG, Virani SA, Jhund PS, Petrie MC, Hawkins NM. Heart failure and atrial flutter: a systematic review of current knowledge and practices. ESC Heart Fail. 2021;8(6):4484-96.
25. Pizzale S, Lemery R, Green MS, Gollob MH, Tang AS, Birnie DH. Frequency and predictors of tachycardia-induced cardiomyopathy in patients with persistent atrial flutter. Can J Cardiol. 2009;25(8):469-72.
26. Oka S, Kai T, Hoshino K, Watanabe K, Nakamura J, Abe M, et al. Rate Versus Rhythm Control in Tachycardia-Induced Cardiomyopathy Patients with Persistent Atrial Flutter. Int Heart J. 2021;62(1):119-26.
27. Brugada J, Katritsis DG, Arbelo E, Arribas F, Bax JJ, Blomstrom-Lundqvist C, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(5):655-720.
28. Natale A, Newby KH, Pisanó E, Leonelli F, Fanelli R, Potenza D, et al. Prospective randomized comparison of antiarrhythmic therapy versus first-line radiofrequency ablation in patients with atrial flutter. J Am Coll Cardiol. 2000;35(7):1898-904.
29. Huizar JF, Ellenbogen KA, Tan AY, Kaszala K. Arrhythmia-Induced Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;73(18):2328-44.
30. Huizar JF, Kaszala K, Potfay J, Minisi AJ, Lesnefsky EJ, Abbate A, et al. Left ventricular systolic dysfunction induced by ventricular ectopy: a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(4):543-9.
31. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia-Induced Cardiomyopathies: Mechanisms, Recognition, and Management. J Am Coll Cardiol. 2015;66(15):1714-28.
32. Del Carpio Munoz F, Syed FF, Noheria A, Cha YM, Friedman PA, Hammill SC, et al. Characteristics of premature ventricular complexes as correlates of reduced left ventricular systolic function: study of the burden, duration, coupling interval, morphology and site of origin of PVCs. J Cardiovasc Electrophysiol. 2011;22(7):791-8.
33. Latchamsetty R, Yokokawa M, Morady F, Kim HM, Mathew S, Tilz R, et al. Multicenter Outcomes for Catheter Ablation of Idiopathic Premature Ventricular Complexes. JACC Clin Electrophysiol. 2015;1(3):116-23.